IO Biotech expects Phase 3 PFS readout in Q3 2025; cash of $60M extends runway to Q2 2026

IO Biotech, Inc.

Phase 3 trial (advanced melanoma) PFS primary endpoint readout delayed to Q3 2025; BLA submission still planned by year-end 2025.
Cash and equivalents ~$60M as of Dec 31, 2024; secured up to €57.5M EIB debt, extending runway into Q2 2026.
Phase 2 basket trial (resectable melanoma/SCCHN) enrollment completed at 95 patients; initial data expected H2 2025.
Phase 2 IOB-022 met primary endpoint ORR in SCCHN; promising PFS in SCCHN and NSCLC; longer-term data H2 2025.

item 2.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-045673
form_type: 8-K
ticker: IOBTQ
cik: 0001865494
company_name: IO Biotech, Inc.
filed_at: 2025-03-04T23:59:59+00:00
discovered_at: 2026-05-14T18:03:05.375288+00:00
generated_at: 2026-05-25T15:40:43.889539+00:00
sec_items: ["2.02", "7.01", "9.01"]
event_type: other_material
sentiment: negative
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-045673
json_url: https://secwatch.observer/filing/0001193125-25-045673.json
markdown_url: https://secwatch.observer/filing/0001193125-25-045673.md
text_url: https://secwatch.observer/filing/0001193125-25-045673.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312525045673/0001193125-25-045673-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312525045673/d924521d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-045673

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.